Zealand Pharma Generate Biomedicines Deal: Powerful AI Pact
Zealand Pharma Generate Biomedicines deal: $30M upfront and up to nearly $1.2B in potential milestones for AI-designed obesity drugs. Nothing is guaranteed.
Iambic Therapeutics IPO Targets $806M Valuation
Nvidia-backed Iambic Therapeutics plans a Nasdaq IPO at $15 to $17 a share, valuing the AI drug discovery firm at up to about $806 million.